{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T08:08:41Z","timestamp":1779350921168,"version":"3.51.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007653","name":"Universit\u00e4tsklinikum Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007653","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Mirvetuximab soravtansine (MIRV) is an antibody\u2013drug conjugate targeting the folate receptor \u03b1 (FR\u03b1), approved for FR\u03b1-positive platinum-resistant ovarian cancer based on improved progression-free and overall survival and higher response rates compared with standard therapy in the MIRASOL trial. The aim of the present study was to provide a health economic evaluation of MIRV from the perspective of the statutory health insurance in Germany.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and findings<\/jats:title>\n                    <jats:p>A Markov state-transition model with three health states (stable, progressive, dead) was used with a time horizon of fives years. Transition probabilities were derived from published Kaplan\u2013Meier survival curves of the MIRASOL trial. Direct costs and literature-based utilities were applied. Cost-effectiveness was assessed using the incremental cost-effectiveness ratio (ICER) and the incremental cost-utility ratio (ICUR). Deterministic and probabilistic sensitivity analyses addressed the uncertainty of the model. In the base case, MIRV resulted in an incremental gain of 0.408 life years (LYs) or 0.226 quality-adjusted life years (QALYs) compared to standard therapy. Incremental costs of \u20ac128,338.84 were incurred. This resulted in an ICER of \u20ac314,753.36 per additional LYs and \u20ac567,734.77 per QALY. All analyzed scenarios exceeded the defined threshold, of three times the German gross domestic product per capita, with the drug price having the greatest influence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MIRV is highly likely to be a more effective treatment option than the chemotherapies currently available for patients with FR\u03b1-positive, platinum-resistant ovarian cancer, as approximately 75\u201390% of ovarian cancers are FR\u03b1-positive. However, in the current circumstances, MIRV is unlikely to be considered cost-effective within the German healthcare context without reduction in the drug price.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-026-06488-8","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T02:43:43Z","timestamp":1779331423000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health economic evaluation of Mirvetuximab soravtansine for the treatment of FR\u03b1-positive, platinum resistant ovarian cancer in Germany"],"prefix":"10.1007","volume":"152","author":[{"given":"Franz F.","family":"Janke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross J.","family":"Baldessarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Bauerschlag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Zibolka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"6488_CR1","doi-asserted-by":"publisher","first-page":"A645","DOI":"10.1016\/j.jval.2014.08.2337","volume":"17","author":"I Al-Dakkak","year":"2014","unstructured":"Al-Dakkak I, Borrill J, Murphy E, Posnett J, Zhang Y (2014) A systematic review of health state utility values for advanced ovarian cancer. Value Health 17:A645. https:\/\/doi.org\/10.1016\/j.jval.2014.08.2337","journal-title":"Value Health"},{"key":"6488_CR2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/MLR.0b013e31815c31a7","volume":"46","author":"RS Braithwaite","year":"2008","unstructured":"Braithwaite RS, Meltzer DO, King JT, Leslie D, Roberts MS (2008) What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 46:349\u2013356. https:\/\/doi.org\/10.1097\/MLR.0b013e31815c31a7","journal-title":"Med Care"},{"key":"6488_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2165\/00019053-200017050-00006","volume":"17","author":"AH Briggs","year":"2000","unstructured":"Briggs AH (2000) Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17:479\u2013500. https:\/\/doi.org\/10.2165\/00019053-200017050-00006","journal-title":"Pharmacoeconomics"},{"key":"6488_CR4","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jval.2012.04.014","volume":"15","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, Weinstein MC, Fenwick EAL, Karnon J, Sculpher MJ, Paltiel AD (2012) Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6. Value Health 15:835\u2013842. https:\/\/doi.org\/10.1016\/j.jval.2012.04.014","journal-title":"Value Health"},{"key":"6488_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15133470","volume":"15","author":"MT Climent","year":"2023","unstructured":"Climent MT, Serra A, Llueca M, Llueca A (2023) Surgery in recurrent ovarian cancer: a meta-analysis. Cancers (Basel) 15:00. https:\/\/doi.org\/10.3390\/cancers15133470","journal-title":"Cancers (Basel)"},{"key":"6488_CR6","doi-asserted-by":"publisher","unstructured":"DKR(2023) Krebs in Deutschland 2023 \u2013 Kapitel C56: Eierst\u00f6cke. Berlin https:\/\/doi.org\/10.25646\/13129","DOI":"10.25646\/13129"},{"key":"6488_CR7","unstructured":"DRG Research Group (2025) Web-Grouper \u2013 DRG Research Group. DRG Research Group. https:\/\/www.drg-research-group.de\/index.php?option=com_webgrouper&view=webgrouper&Itemid=107. Accessed 9 June 2025"},{"key":"6488_CR8","unstructured":"European Medicines Agency (EMA) (2023) Elahere: EPAR \u2013 Public assessment report. European Medicines Agency (EMA). https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elahere. Accessed 9 June 2025"},{"key":"6488_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2024-esgo.43","author":"YG Garcia","year":"2024","unstructured":"Garcia YG, Van Gorp T, Konecny GE, Leary A, Santin AD, Crusz SM, Mantia-Smaldone G, Lorusso D, Colombo N, Thomes-Pepin J, Roszak A, Ottevanger PB, Beiner M, Cibula D, Leath C, Li L, Method M, Moore KN (2024) 360 Health-related quality of life in patients with FR\u03b1 positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs investigator\u2019s choice chemotherapy: analysis from the phase 3 MIRASOL trial. BMJ. https:\/\/doi.org\/10.1136\/ijgc-2024-esgo.43","journal-title":"BMJ"},{"key":"6488_CR10","unstructured":"GKV-Spitzenverband (2025) Rechtlich unverbindliche Lesefassung Anlage\u202f3 zum Vertrag Hilfstaxe. https:\/\/www.gkv-spitzenverband.de\/media\/dokumente\/krankenversicherung_1\/arzneimittel\/rahmenvertraege\/hilfstaxe\/2025-03-01_Rechtlich_unverbindliche_Lesefassung_Anlage_3_zum_Vertrag_Hilfstaxe_idF_36._EV.pdf. Accessed 26 June 2025"},{"key":"6488_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3111\/13696998.2016.1151432","volume":"19","author":"R Goeree","year":"2016","unstructured":"Goeree R, Villeneuve J, Goeree J, Penrod JR, Orsini L, Tahami Monfared AA (2016) Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes. J Med Econ 19:630\u2013644. https:\/\/doi.org\/10.3111\/13696998.2016.1151432","journal-title":"J Med Econ"},{"key":"6488_CR12","unstructured":"Gemeinsamer Bundesausschuss (GBA) (2025) Nutzenbewertung von Arzneimitteln gem\u00e4\u00df \u00a7 35a SGB V (AMNOG). https:\/\/www.g-ba.de\/themen\/arzneimittel\/arzneimittel-richtlinie-anlagen\/nutzenbewertung-35a\/. Accessed 25 Aug 2025"},{"key":"6488_CR13","unstructured":"Gemeinsamer Bundesausschuss (GBA) (2025) Nutzenbewertung f\u00fcr Orphan Drugs: Mirvetuximab Soravtansin (Version 1.0). Berlin https:\/\/www.g-ba.de\/downloads\/92-975-8214\/2024-12-15_Nutzenbewertung-G-BA_Mirvetuximab-Soravtasin_D-1131.pdf"},{"key":"6488_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-10956-6","author":"LR Hallsson","year":"2023","unstructured":"Hallsson LR, Sroczynski G, Engel J, Siebert U (2023) Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1\/2 mutations. BMC Cancer. https:\/\/doi.org\/10.1186\/s12885-023-10956-6","journal-title":"BMC Cancer"},{"key":"6488_CR15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.ygyno.2008.12.026","volume":"113","author":"LJ Havrilesky","year":"2009","unstructured":"Havrilesky LJ, Broadwater G, Davis DM, Nolte KC, Barnett JC, Myers ER, Kulasingam S (2009) Determination of quality of life-related utilities for health states relevant to ovarian cancer diagnosis and treatment. Gynecol Oncol 113:216\u2013220. https:\/\/doi.org\/10.1016\/j.ygyno.2008.12.026","journal-title":"Gynecol Oncol"},{"key":"6488_CR16","unstructured":"Institut f\u00fcr Qualit\u00e4t und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2023) Allgemeine Methoden \u2013 Version 7.0. IQWiG 2023 https:\/\/www.iqwig.de\/methoden\/allgemeine-methoden_version-7-0.pdf. Accessed 9 June 2025"},{"key":"6488_CR17","unstructured":"Institute for Clinical and Economic Review (2024) ICER Value Assessment Framework: Reference Case Specifications and Reporting Guidelines. https:\/\/icer.org\/wp-content\/uploads\/2024\/02\/Reference-Case-4.3.25.pdf. Accessed 26 June 2025"},{"key":"6488_CR18","unstructured":"International Agency for Research on Cancer (2024) Germany \u2013 Fact Sheet. World Health Organization 2024. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/276-germany-fact-sheet.pdf. Accessed 9 June 2025"},{"key":"6488_CR19","unstructured":"International Agency for Research on Cancer (2024) Ovary \u2013 Fact Sheet. World Health Organization 2024. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/cancers\/25-ovary-fact-sheet.pdf. Accessed 9 June 2025"},{"key":"6488_CR20","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40273-013-0064-3","volume":"31","author":"KJ Ishak","year":"2013","unstructured":"Ishak KJ, Kreif N, Benedict A, Muszbek N (2013) Overview of parametric survival analysis for health-economic applications. Pharmacoeconomics 31:663\u2013675. https:\/\/doi.org\/10.1007\/s40273-013-0064-3","journal-title":"Pharmacoeconomics"},{"key":"6488_CR21","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1002\/ijc.33395","volume":"148","author":"R Kessous","year":"2021","unstructured":"Kessous R, Wissing MD, Laskov I, Abitbol J, Bitharas J, Agnihotram VR, Yasmeen A, Salvador S, Lau S, Gotlieb WH (2021) Multiple lines of chemotherapy for patients with high\u2010grade ovarian cancer: predictors for response and effect on survival. Int J Cancer 148:2304\u20132312. https:\/\/doi.org\/10.1002\/ijc.33395","journal-title":"Int J Cancer"},{"key":"6488_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01686-2","author":"B Kong","year":"2025","unstructured":"Kong B, Zheng W (2025) Mirvetuximab Soravtansine: current and future applications. J Hematol Oncol. https:\/\/doi.org\/10.1186\/s13045-025-01686-2","journal-title":"J Hematol Oncol"},{"key":"6488_CR23","unstructured":"Kassen\u00e4rztliche Bundesvereinigung (KBV) (2025) EBM \u2013 Einheitlicher\u202fBewertungsma\u00dfstab \u2013 KBV. https:\/\/www.kbv.de\/html\/ebm.php. Accessed 26 June 2025"},{"key":"6488_CR24","unstructured":"Kassen\u00e4rztliche Bundesvereinigung (KBV) (2025) Einheitlicher Bewertungsma\u00dfstab (EBM) \u2013 Online-Katalog. KBV. https:\/\/ebm.kbv.de\/. Accessed 9 June 2025"},{"key":"6488_CR25","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989X12472398","volume":"33","author":"NR Latimer","year":"2013","unstructured":"Latimer NR (2013) Survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making 33:743\u2013754. https:\/\/doi.org\/10.1177\/0272989X12472398","journal-title":"Med Decis Making"},{"key":"6488_CR26","doi-asserted-by":"publisher","unstructured":"Ludwig W-D, M\u00fchlbauer B, Seifert R (2024) Arzneiverordnungs-Report\u00a02023. Berlin & Heidelberg, Germany: Springer Berlin\u202fHeidelberg; 2024. https:\/\/doi.org\/10.1007\/978-3-662-68371-2.","DOI":"10.1007\/978-3-662-68371-2"},{"key":"6488_CR27","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DKA. S3-Leitlinie Supportive Therapie bei onkologischen PatientInnen. Berlin: 2020. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/Downloads\/Leitlinien\/Supportivtherapie\/Version_1\/LL_Supportiv_Langversion_1.3.pdf"},{"key":"6488_CR28","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1200\/JCO.22","volume":"41","author":"UA Matulonis","year":"2023","unstructured":"Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Toon VG, Konner JA, Margarita RM, Harter P, Conleth GM, Wang J, Noble E, Esteves B, Method M, Coleman RL (2023) Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study. J Clin Oncol 41:2436\u20132445. https:\/\/doi.org\/10.1200\/JCO.22","journal-title":"J Clin Oncol"},{"key":"6488_CR29","doi-asserted-by":"publisher","unstructured":"MikiK, Moriwaki K, Morimoto K, Kashiwa M, Shimozuma K (2025) Cost-effectiveness analysis of mirvetuximab soravtansine in FR\u03b1-positive platinum-resistant ovarian cancer in Japan. Value in Health. 28(S1): Abstract EE268, Montr\u00e9al, Quebec, Canada: ISPOR 2025; 2025. https:\/\/doi.org\/10.1016\/j.jval.2025.04.1867","DOI":"10.1016\/j.jval.2025.04.1867"},{"key":"6488_CR30","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore KN, Oza AM, Colombo N, Oaknin A, Scambia G, Lorusso D, Konecny GE, Banerjee S, Murphy CG, Tanyi JL, Hirte H, Konner JA, Lim PC, Prasad-Hayes M, Monk BJ, Pautier P, Wang J, Berkenblit A, Vergote I, Birrer MJ (2021) Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann Oncol 32:757\u2013765. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.017","journal-title":"Ann Oncol"},{"key":"6488_CR31","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1056\/nejmoa2309169","volume":"389","author":"KN Moore","year":"2023","unstructured":"Moore KN, Angelergues A, Konecny GE, Garc\u00eda Y, Banerjee S, Lorusso D, Lee J-Y, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee J-W, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Est\u00e9vez-Garc\u00eda P, Coffman L, Nicum S, Duska LR, Pignata S, G\u00e1lvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T (2023) Mirvetuximab Soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer. N Engl J Med 389:2162\u20132174. https:\/\/doi.org\/10.1056\/nejmoa2309169","journal-title":"N Engl J Med"},{"key":"6488_CR32","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMp1612619","volume":"376","author":"PJ Neumann","year":"2017","unstructured":"Neumann PJ, Sanders GD (2017) Cost-effectiveness analysis 2.0. N Engl J Med 376:203\u2013205. https:\/\/doi.org\/10.1056\/NEJMp1612619","journal-title":"N Engl J Med"},{"key":"6488_CR33","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ygyno.2020.09.051","volume":"160","author":"A Nica","year":"2021","unstructured":"Nica A, Lee JYJ, Hong NL, May T (2021) Cost-effectiveness of maintenance hormonal therapy in patients with advanced low grade serous ovarian cancer. Gynecol Oncol 160:206\u2013213. https:\/\/doi.org\/10.1016\/j.ygyno.2020.09.051","journal-title":"Gynecol Oncol"},{"key":"6488_CR34","unstructured":"National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version\u202f5.0 \u2013 Quick Reference 5\u00d77. US Department of Health and Human Services. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 9 June 2025"},{"key":"6488_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0278460","author":"F Schwarz","year":"2022","unstructured":"Schwarz F, Arefian H, Hartmann M, Runnebaum I (2022) Cost-effectiveness of Talazoparib for patients with locally advanced or metastasized breast cancer in Germany. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0278460","journal-title":"PLoS ONE"},{"key":"6488_CR36","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"FA Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322\u2013338. https:\/\/doi.org\/10.1177\/0272989X9301300409","journal-title":"Med Decis Making"},{"key":"6488_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-662-46764-0_365-1","volume-title":"Gesundheits\u00f6konomie in der H\u00e4matologie und Onkologie","author":"TD Szucs","year":"2021","unstructured":"Szucs TD, Arefian H, Hartmann M (2021) Gesundheits\u00f6konomie in der H\u00e4matologie und Onkologie. pp 1\u20138. https:\/\/doi.org\/10.1007\/978-3-662-46764-0_365-1"},{"key":"6488_CR38","unstructured":"Statistisches Bundesamt (Destatis) (2023) K\u00f6rperma\u00dfe der Bev\u00f6lkerung nach Altersgruppen und Geschlecht \u2013 Mikrozensus 2021. Statistisches Bundesamt. https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Gesundheit\/Gesundheitszustand-Relevantes-Verhalten\/Tabellen\/liste-koerpermasse.html. Accessed 9 June 2025"},{"key":"6488_CR39","unstructured":"Statistisches Bundesamt (Destatis) (2024) Sterbetafeln 2021\/2023 \u2013 Periodensterbetafel \u2013 Deutschland, Ost- und Westdeutschland und Bundesl\u00e4nder. Statistisches Bundesamt. https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Bevoelkerung\/Sterbefaelle-Lebenserwartung\/Tabellen\/_tabellen-innen-lebenserwartung-sterbetafel.html. Accessed 9 June 2025"},{"key":"6488_CR40","unstructured":"Statistisches Bundesamt (Destatis) (2025) Volkswirtschaftliche Gesamtrechnungen - Bruttoinlandsprodukt (BIP). Statistisches Bundesamt. https:\/\/www.destatis.de\/DE\/Themen\/Wirtschaft\/Volkswirtschaftliche-Gesamtrechnungen-Inlandsprodukt\/Tabellen\/bip-bubbles.html#fussnote-4-372912. Accessed 9 June 2025"},{"key":"6488_CR41","unstructured":"Tunder R, Martschinke B (2016) Die Beurteilung des Arzneimittelmarkt-Neuordnungsgesetzes (AMNOG) aus Sicht der gesetzlichen Krankenkassen https:\/\/hdl.handle.net\/10419\/130542"},{"key":"6488_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S1470-2045(25)00021-X","volume":"26","author":"T Van Gorp","year":"2025","unstructured":"Van Gorp T, Moore KN, Konecny GE, Leary A, Garc\u00eda-Garc\u00eda Y, Banerjee S, Lorusso D, Lee J-Y, Moroney JW, Caruso G, Klasa-Mazurkiewicz D, Tromp J, Martin LP, Breuer S, Leath IIICA, Cibula D, Weroha SJ, Est\u00e9vez-Garc\u00eda Y, O\u2019Malley DM, Miller RE, Coffman L, Scandurra G, Berton D, Li L, Zagadailov J, Diver EJ, Tr\u00e9dan O, Hilpert F (2025) Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor &amp;#x3b1;-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncol 26:503\u2013515. https:\/\/doi.org\/10.1016\/S1470-2045(25)00021-X","journal-title":"Lancet Oncol"},{"key":"6488_CR43","unstructured":"Volk J (2018) Chancen und Determinanten gesundheits\u00f6konomischer Evaluation im Rahmen des Arzneimittelmarkt-Neuordnungsgesetzes (AMNOG). Dissertation. Universit\u00e4t Bayreuth"},{"key":"6488_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-018-0156-1","volume":"16","author":"YV Yong","year":"2018","unstructured":"Yong YV, Shafie AA (2018) Using a dynamic adherence Markov model to assess the efficiency of Respiratory Medication Therapy Adherence Clinic (RMTAC) on asthma patients in Malaysia. Cost Eff Resour Alloc 16:36. https:\/\/doi.org\/10.1186\/s12962-018-0156-1","journal-title":"Cost Eff Resour Alloc"},{"key":"6488_CR45","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2024.35.e71","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Lin Y, Liu K, Zhu H (2024) Mirvetuximab soravtansine in platinum-resistant recurrent ovarian cancer with high folate receptor-alpha expression: a cost-effectiveness analysis. J Gynecol Oncol. https:\/\/doi.org\/10.3802\/jgo.2024.35.e71","journal-title":"J Gynecol Oncol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06488-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06488-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06488-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:29:19Z","timestamp":1779348559000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06488-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["6488"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06488-8","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"7 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"111"}}